These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34512672)

  • 1. HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
    Kammers K; Chen A; Monaco DR; Hudelson SE; Grant-McAuley W; Moore RD; Alter G; Deeks SG; Morrison CS; Eller LA; Blankson JN; Laeyendecker O; Ruczinski I; Eshleman SH; Larman HB
    Front Immunol; 2021; 12():740395. PubMed ID: 34512672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of antibody targets associated with lower HIV viral load and viremic control.
    Grant-McAuley W; Morgenlander WR; Ruczinski I; Kammers K; Laeyendecker O; Hudelson SE; Thakar M; Piwowar-Manning E; Clarke W; Breaud A; Ayles H; Bock P; Moore A; Kosloff B; Shanaube K; Meehan SA; van Deventer A; Fidler S; Hayes R; Larman HB; Eshleman SH;
    PLoS One; 2024; 19(9):e0305976. PubMed ID: 39288118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load.
    Grant-McAuley W; Morgenlander W; Hudelson SE; Thakar M; Piwowar-Manning E; Clarke W; Breaud A; Blankson J; Wilson E; Ayles H; Bock P; Moore A; Kosloff B; Shanaube K; Meehan SA; van Deventer A; Fidler S; Hayes R; Ruczinski I; Kammers K; Laeyendecker O; Larman HB; Eshleman SH
    Front Immunol; 2023; 14():1178520. PubMed ID: 37744365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers.
    de Mulder M; SenGupta D; Deeks SG; Martin JN; Pilcher CD; Hecht FM; Sacha JB; Nixon DF; Michaud HA
    Retrovirology; 2017 Aug; 14(1):41. PubMed ID: 28830571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
    Salgado M; Garcia-Minambres A; Dalmau J; Jiménez-Moyano E; Viciana P; Alejos B; Clotet B; Prado JG; Martinez-Picado J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.
    Madhavi V; Wren LH; Center RJ; Gonelli C; Winnall WR; Parsons MS; Kramski M; Kent SJ; Stratov I
    AIDS; 2014 Aug; 28(13):1859-70. PubMed ID: 24937308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
    Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
    PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.
    Sunshine J; Kim M; Carlson JM; Heckerman D; Czartoski J; Migueles SA; Maenza J; McElrath MJ; Mullins JI; Frahm N
    J Virol; 2014 Jan; 88(2):1354-65. PubMed ID: 24227851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.
    Kant S; Zhang N; Barbé A; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Harris M; Dupuy FP; Bernard NF
    Front Immunol; 2020; 11():583820. PubMed ID: 33101312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy.
    Zhang W; Morshed MM; Noyan K; Russom A; Sönnerborg A; Neogi U
    Sci Rep; 2017 Apr; 7(1):666. PubMed ID: 28386076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage.
    Buggert M; Norström MM; Czarnecki C; Tupin E; Luo M; Gyllensten K; Sönnerborg A; Lundegaard C; Lund O; Nielsen M; Karlsson AC
    PLoS One; 2012; 7(7):e39874. PubMed ID: 22792193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.
    Shang F; Huang H; Revesz K; Chen HC; Herz R; Pinter A
    J Virol; 1991 Sep; 65(9):4798-804. PubMed ID: 1714518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid development of HIV elite control in a patient with acute infection.
    Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
    BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
    Jilg N; Garcia-Broncano P; Peluso M; Segal FP; Bosch RJ; Roberts-Toler C; Chen SMY; Van Dam CN; Keefer MC; Kuritzkes DR; Landay AL; Deeks S; Yu XG; Sax PE; Li JZ;
    J Infect Dis; 2020 Nov; 222(11):1837-1842. PubMed ID: 32496516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
    Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
    J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
    de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.